Clinical Trials Browser

INDUSTRY × Interventional × efgartigimod alfa × Clear all

NCT07217587 2026-03-13

EPIC

Phase 3 Recruiting

Myasthenia Gravis

NCT02965573 2024-08-28

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Phase 2 Completed

24 enrolled 28 charts

Myasthenia Gravis

NCT03770403 2023-07-14

ADAPT+

Phase 3 Completed

151 enrolled 11 charts

Myasthenia Gravis

NCT03669588 2022-02-08

ADAPT

Phase 3 Completed

167 enrolled 18 charts

Myasthenia Gravis